Akari's lead drug candidate, Nomacopan, is a C5 complement inhibitor that also specifically inhibits leukotriene B4 (LTB4) activity, and is currently being clinically evaluated in four areas, including bullous pemphigoid (BP) and thrombotic microangiopathy (TMA). The company's pipeline includes pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA), and it operates mainly in the United States and United Kingdom.